On Tuesday, PDS Biotechnology Corporation (NASDAQ: PDSB) was 8.51% up from the session before settling in for the closing price of $1.41. A 52-week range for PDSB has been $0.85 – $4.42.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
When this article was written, the company’s average yearly earnings per share was at 17.15%. With a float of $43.98 million, this company’s outstanding shares have now reached $45.45 million.
Let’s look at the performance matrix of the company that is accounted for 24 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
PDS Biotechnology Corporation (PDSB) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward PDS Biotechnology Corporation stocks. The insider ownership of PDS Biotechnology Corporation is 3.78%, while institutional ownership is 18.00%. The most recent insider transaction that took place on Feb 28 ’25, was worth 25,000. In this transaction Director of this company bought 15,060 shares at a rate of $1.66, taking the stock ownership to the 61,213 shares. Before that another transaction happened on Feb 28 ’25, when Company’s Director bought 15,061 for $1.66, making the entire transaction worth $25,001. This insider now owns 78,851 shares in total.
PDS Biotechnology Corporation (PDSB) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 17.15% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 6.45% during the next five years compared to 6.42% growth over the previous five years of trading.
PDS Biotechnology Corporation (NASDAQ: PDSB) Trading Performance Indicators
You can see what PDS Biotechnology Corporation (PDSB) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 2.33.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.94, a number that is poised to hit -0.22 in the next quarter and is forecasted to reach -0.85 in one year’s time.
Technical Analysis of PDS Biotechnology Corporation (PDSB)
PDS Biotechnology Corporation (NASDAQ: PDSB) saw its 5-day average volume 0.57 million, a negative change from its year-to-date volume of 0.57 million. As of the previous 9 days, the stock’s Stochastic %D was 25.29%. Additionally, its Average True Range was 0.12.
During the past 100 days, PDS Biotechnology Corporation’s (PDSB) raw stochastic average was set at 50.37%, which indicates a significant decrease from 55.24% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 79.49% in the past 14 days, which was lower than the 95.34% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.2552, while its 200-day Moving Average is $2.0577. Nevertheless, the first resistance level for the watch stands at $1.5800 in the near term. At $1.6300, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.7300. If the price goes on to break the first support level at $1.4300, it is likely to go to the next support level at $1.3300. The third support level lies at $1.2800 if the price breaches the second support level.
PDS Biotechnology Corporation (NASDAQ: PDSB) Key Stats
There are 45,710K outstanding shares of the company, which has a market capitalization of 69.94 million. As of now, sales total 0 K while income totals -37,610 K. Its latest quarter income was 0 K while its last quarter net income were -8,490 K.
